Recent developments on triazole nucleus in anticonvulsant compounds: a review.
Recent developments on triazole nucleus in anticonvulsant compounds: a review.
复制标题
抗惊厥化合物中三唑核的最新进展：综述
DOI：
10.1080/14756366.2017.1423068
复制
发表时间：
2018-12
影响因子：
5.6
通讯作者：
Deng XQ
中科院分区：
文献类型：
--
作者：
Song MX;Deng XQ
摘要癫痫是严重威胁人类生命健康的常见病之一。超过5000万人患有这种疾病，抗惊厥药物是主要的治疗方法。然而，副作用和不耐受性以及缺乏疗效限制了当前抗惊厥剂的应用。寻找新的高效低毒的抗惊厥药物一直是药物化学研究的重点和任务。大量的三唑衍生物作为临床药物或候选药物被广泛应用于各种疾病的治疗，证明了这类杂环核在药物设计和发现中的重要性。近年来，人们将三唑类化合物引入抗惊厥药物的设计中，产生了许多具有抗惊厥活性的化合物。本文系统地综述了近二十年来三唑类化合物在抗惊厥药物设计和开发中的研究进展。
Abstract Epilepsy is one of the common diseases seriously threatening life and health of human. More than 50 million people are suffering from this condition and anticonvulsant agents are the main treatment. However, side effects and intolerance, and a lack of efficacy limit the application of the current anticonvulsant agents. The search for new anticonvulsant agents with higher efficacy and lower toxicity continues to be the focus and task in medicinal chemistry. Numbers of triazole derivatives as clinical drugs or candidates have been frequently employed for the treatment of various types of diseases, which have proved the importance of this heterocyclic nucleus in drug design and discovery. Recently many endeavours were made to involve the triazole into the anticonvulsants design, which have brought lots of active compounds. This work is an attempt to systematically review the research of triazole derivatives in the design and development of anticonvulsant agents during the past two decades.
登录
查看更多内容
影响因子：
3.6
作者：
Abou-Khalil, Bassel W
通讯作者：
Abou-Khalil, Bassel W
DOI：
10.1155/2013/587054
发表时间：
2013
期刊：
ISRN organic chemistry
影响因子：
--
作者：
Alswah M;Ghiaty A;El-Morsy A;El-Gamal K
通讯作者：
El-Gamal K
DOI：
10.1039/j39670001664
发表时间：
1967-01-01
期刊：
JOURNAL OF THE CHEMICAL SOCIETY C-ORGANIC
影响因子：
--
作者：
BARTLETT, RK;HUMPHREY, IR
通讯作者：
HUMPHREY, IR
影响因子：
1.7
作者：
Catarzi, Daniela;Lenzi, Ombretta;Ofner, Silvio
通讯作者：
Ofner, Silvio
影响因子：
7.3
作者：
Chimirri, A;DeSarro, G;Chapman, AG
通讯作者：
Chapman, AG